Company Analysis

Cue Biopharma, Inc. (CUE)

Nasdaq: CUE · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2015
Grade4.8
◀ Past 4.0● Present 4.0▶ Future 6.7
1 est.

Filings

285 filings since 2017 beside 264 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company
10-Q Quarterly report for the quarter ending Sep 30, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by Nov 14, 2026
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 45 days after the quarter ended. The proxy statement was last filed May 21, 2026.

Filings a yearinsider forms included
5757474743515391
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 14 times in the last 36 months, the newest Aug 3, 2026.Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest Aug 16, 2024.SEC letters: 11 in the last 36 months, the newest Aug 18, 2026.
Insider forms 264

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 10, 2026 SCHEDULE 13G/A Large holder update, amended
Oct 8, 2026 SCHEDULE 13G/A Large holder update, amended
Sep 21, 2026 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report Sep 20, 2026
Aug 21, 2026 SCHEDULE 13D Activist holder notice
Aug 20, 2026 EFFECT Registration effective
Aug 18, 2026 CORRESP Reply to the SEC
Aug 17, 2026 UPLOAD SEC comment letter
Aug 14, 2026 10-Q Quarterly report Jun 30, 2026
Aug 14, 2026 8-K item 2.02 Results released · Current report
Aug 14, 2026 SCHEDULE 13G Large holder notice
Aug 12, 2026 S-3 Shelf registration
Aug 3, 2026 8-K item 5.02 Officer or director change · Current report Jul 27, 2026
Jul 22, 2026 D Private placement notice
Jul 10, 2026 8-K items 1.01, 3.02, 5.02, 8.01, 9.01 Major agreement signed; Shares sold without registration; Officer or director change; Other event · Current report Jul 9, 2026
Jul 1, 2026 EFFECT Registration effective
Jun 29, 2026 CORRESP Reply to the SEC
Jun 25, 2026 UPLOAD SEC comment letter
Jun 18, 2026 S-3 Shelf registration
Jun 17, 2026 EFFECT Registration effective
Jun 15, 2026 CORRESP Reply to the SEC
Jun 10, 2026 UPLOAD SEC comment letter
Jun 3, 2026 8-K items 5.02, 5.07, 9.01 Officer or director change; Shareholder vote · Current report Jun 1, 2026
Jun 3, 2026 S-8 Employee stock plan registration
Jun 3, 2026 S-3 Shelf registration
Jun 2, 2026 8-K items 5.02, 8.01 Officer or director change; Other event · Current report May 29, 2026
May 21, 2026 DEF 14A Proxy statement Jun 1, 2026
May 14, 2026 D Private placement notice
May 14, 2026 8-K item 9.01 Financial statements and exhibits · Current report
May 14, 2026 10-Q Quarterly report Mar 31, 2026
May 11, 2026 PRE 14A Preliminary proxy statement Jun 1, 2026
May 1, 2026 S-8 Employee stock plan registration
May 1, 2026 8-K items 1.01, 3.02, 5.02, 8.01, 9.01 Major agreement signed; Shares sold without registration; Officer or director change; Other event · Current report Apr 27, 2026
Apr 22, 2026 8-K items 3.03, 5.03 Change to shareholders' rights; Charter, bylaw or fiscal-year change · Current report
Apr 13, 2026 8-K item 5.07 Shareholder vote · Current report
Apr 7, 2026 8-K item 8.01 Other event · Current report Apr 1, 2026
Mar 31, 2026 EFFECT Registration effective
Mar 27, 2026 CORRESP Reply to the SEC
Mar 27, 2026 DEFA14A Extra proxy material
Mar 27, 2026 8-K item 5.02 Officer or director change · Current report Mar 23, 2026
Mar 23, 2026 UPLOAD SEC comment letter
40 of 285 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton CUE · research, not advice